WO2011107921A2 - Composition de milnacipran à libération modifiée - Google Patents

Composition de milnacipran à libération modifiée Download PDF

Info

Publication number
WO2011107921A2
WO2011107921A2 PCT/IB2011/050825 IB2011050825W WO2011107921A2 WO 2011107921 A2 WO2011107921 A2 WO 2011107921A2 IB 2011050825 W IB2011050825 W IB 2011050825W WO 2011107921 A2 WO2011107921 A2 WO 2011107921A2
Authority
WO
WIPO (PCT)
Prior art keywords
milnacipran
composition
modified release
unit
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2011/050825
Other languages
English (en)
Other versions
WO2011107921A3 (fr
Inventor
Sumit Madan
Vinod Kumar Arora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2011107921A2 publication Critical patent/WO2011107921A2/fr
Publication of WO2011107921A3 publication Critical patent/WO2011107921A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Definitions

  • the present invention relates to a modified release composition, which includes milnacipran or its pharmaceutically acceptable salts, and process for their preparation.
  • Milnacipran is chemically known as (+)-c/s-2-amino methyl-N, N-diethyl-1- phenyl cyclopropane carboxamide.
  • Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) with negligible effects on any presynaptic or postsynaptic receptors. Milnacipran has unique pharmacokinetic and pharmacodynamic characteristics that distinguish it from the other marketed serotonin and norepinephrine reuptake inhibitors, (z.e.,venlafaxine, desvenlafaxine, and duloxetine) such as equipotent serotonin and norepinephrine reuptake inhibition and a linear dose-concentration trend at therapeutic doses. In addition, milnacipran does not inhibit the cytochrome P 450 system, indicating a minimal propensity for drug-drug interactions.
  • SNRI norepinephrine reuptake inhibitor
  • milnacipran The antidepressant efficacy of milnacipran has been clearly established in a number of randomized, double-blind, placebo-controlled clinical trials, and it has been widely used for treating major depressive disorder. Moreover, evidence suggests that milnacipran is effective and tolerable in the treatment of fibromyalgia and may have usefulness for fatigue and anxiety symptoms.
  • Milnacipran is commercially available as an immediate release formulation in the form of tablets and capsules.
  • the half-life of milnacipran is short, approximately 8 hours. This results in milnacipran being administered twice daily, and because of the adverse effects associated with milnacipran, the dosage needs to be titrated slowly in order to get to the therapeutic dose levels required for treatment.
  • a lack of patient compliance in keeping to this daily dosing schedule is liable to produce discontinuation problems. Sudden discontinuation of milnacipran can result in withdrawal symptoms, which can include dysphoric mood, irritability, agitation, dizziness, sensory
  • milnacipran is an excellent candidate for a modified release oral formulation that can be dosed once a day, thus improving patient compliance.
  • milnacipran is associated with a number of side effects. Milnacipran has demonstrated numerous adverse reactions in human clinical trials with tolerability decreasing with an increasing dose. In the placebo controlled trials in patients with fibromyalgia, the most frequent spontaneously reported adverse events for 100 mg/day & 200 mg/day milnacipran were as follows: nausea (6%), palpitations (3%), headache (2%), constipation (1%), heart rate increased (1%) and hyperhidrosis (1%), vomiting (1%), and dizziness (1% ). Discontinuation due to adverse reactions was generally more common among patients treated with 200 mg/day compared to 100 mg/day. The adverse effects can originate from the fluctuation in the plasma drug concentrations of an active substance following administration and subsequent metabolism and/or elimination from the body.
  • peaks and troughs Such fluctuations can be overcome by administration of the active substance in a controlled release dosage form. In this manner, the active substance is more slowly administered to the body over a much longer period of time. In some instances, the amount of active substance in a controlled release dosage form can be less than that required in an immediate release dosage form and still achieve a comparable therapeutic effect.
  • Sustained release formulations known in the art include specially coated pellets, coated tablets and capsules, and ion exchange resins, wherein the slow release of the active medicament is brought about through selective breakdown of the coating of the preparation or through formulating with a polymeric matrix to affect the release of a drug.
  • Some sustained release formulations provide for pulsatile/sequential release of a single dose of an active compound at predetermined periods after administration.
  • WO 98/08495 discloses a prolonged release formulation of milnacipran, having a multiparticulate form containing plurality of microgranules being coated with a film of water insoluble polymer.
  • WO 2004/037190 discloses a modified release composition of milnacipran providing a delayed release of the active ingredient followed by extended release in the intestine. These compositions start releasing the drug after a lag time followed by sustained release in intestine.
  • WO 2004/067039 discloses a multiparticulate milnacipran composition made by complexing milnacipran with an ion exchange resin in the form of small particles which are coated to give different release profiles.
  • WO 2004/039361 discloses a once a day oral milnacipran pulsatile release composition.
  • the dosage forms have two or three dosage units, having a different drug release profile.
  • a multiple unit type formulation is a formulation having two or more units which are co- present in a single formulation and differ from each other in the drug release rates, as opposed to a single unit type formulation having a single unit.
  • the present invention provides for a modified release composition, which includes:
  • Embodiments of this aspect may include one or more of the following features.
  • the ratio of immediate release unit to the modified release unit(s) ranges from about 5:95 to about 95:5 by weight.
  • the modified release unit may be a controlled release unit, enteric release unit or enteric coated controlled release unit.
  • the composition may also be a two unit system that includes an immediate release unit and one modified release unit.
  • the composition may also be a multiple unit system that includes an immediate release unit and two or more modified release units.
  • the present invention provides for a modified release composition, which includes:
  • Embodiments of this aspect may include one or more of the following features.
  • the ratio of controlled release unit to the enteric release unit(s) may range from about 5:95 to about 95:5 by weight.
  • the enteric release unit may be an enteric coated immediate release unit or an enteric coated controlled release unit.
  • the composition may be a two unit system that includes a controlled release unit and an enteric release unit or an enteric coated controlled release unit.
  • the composition may also be a multiple unit system that includes a controlled release unit, an enteric release unit and an enteric coated controlled release unit.
  • the immediate release unit of the composition may further include one or more pharmaceutically acceptable excipients.
  • the modified release unit of the composition may further include one or more pharmaceutically acceptable excipients and one or more rate-controlling and/or enteric agents.
  • the pharmaceutically acceptable excipients may be one or more of diluents, binders, disintegrants, lubricants, glidants, surfactants, buffers, wetting agents, coloring agents, flavoring agents and combinations thereof.
  • modified release compositions may be in the form of discrete or aggregated particles, pellets, beads or granules.
  • the modified release compositions may be used in the treatment of depression, fibromyalgia syndrome, chronic fatigue syndrome, pain, attention deficit/hyperactivity disorder, and visceral pain syndromes (VPS), noncardiac chest pain (NCCP), functional dyspepsia, interstitial cystitis, essential vulvodynia, urethral syndrome, orchialgia, and affective disorders, including depressive disorders and anxiety disorders, premenstrual dysphoric disorder, temperomandibular disorder, atypical face pain, migraine headache, and tension headache by administering to a person in need thereof.
  • VPN visceral pain syndromes
  • NCP noncardiac chest pain
  • functional dyspepsia interstitial cystitis
  • essential vulvodynia essential vulvodynia
  • urethral syndrome orchialgia
  • affective disorders including depressive disorders and anxiety disorders, premenstrual dysphoric disorder, temperomandibular disorder, atypical face pain, migraine headache,
  • modified release compositions may also be administered in combination with other therapeutic agents.
  • the present invention relates to a modified release composition for the oral administration of milnacipran, which includes:
  • an immediate release unit which includes milnacipran or salts of
  • modified release unit(s) which include milnacipran or salts of milnacipran.
  • the ratio of the immediate release unit to the modified release units may range from about 5:95 to about 95:5 by weight.
  • modified release includes any type of modified release such as prolonged release, sustained release, controlled release, extended release, delayed release and enteric release.
  • modified release agents includes the agents that provide/facilitate modified release such as prolonged release, sustained release, controlled release, extended release, delayed release and enteric release.
  • unit includes spheroids, beads, microspheres, seeds, granules, pellets, mini tablets, ion-exchange resin beads and other multi-particulate systems.
  • the “unit” may also include a mixture of different types of units mentioned here.
  • milnacipran as used herein also encompasses pharmaceutically acceptable, pharmacologically active derivatives of milnacipran including both individual enantiomers of milnacipran (dextrogyral and levrogyral enantiomers) and their pharmaceutically acceptable salts, mixtures of milnacipran enantiomers and their pharmaceutically acceptable salts, and active metabolites of milnacipran and their pharmaceutically acceptable salts, unless otherwise noted.
  • the solid state form of the milnacipran used in the composition of the present invention is not critical.
  • milnacipran can be amorphous or crystalline.
  • the salts of milnacipran used in the composition include salts prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • suitable non-toxic acids include inorganic acids, such as, hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxybenzoic, fumaric, tolunesulfonic, methane sulfonic, ethane disulfonic, oxalic, and isethionic.
  • Particularly suitable is hydrochloric acid.
  • composition of the present invention may be a two unit system, which includes an immediate release unit and a modified release unit or may be a multiple unit system, which includes an immediate release unit and two or more of modified release units.
  • the immediate release units which include milnacipran or salt of milnacipran, can be formulated as a plurality of discrete or aggregated particles, pellets, beads, granules or mini tablets.
  • the process for preparing the units can be accomplished by blending milnacipran or salt of milnacipran with one or more pharmaceutically acceptable excipients using any processes known in the art, such as, simple granulation followed by sieving; extrusion and marumerization or spheronization; rotogranulation; pelletization; micropelletization, etc.
  • the immediate release units are formulated by layering milnacipran or salt of milnacipran with one or more
  • the active ingredient is layered over the inert cores as powder; or as suspension or solution in a suitable solvent.
  • the immediate release unit may also be present as powder.
  • the inert core may be hydrosoluble or hydroinsoluble.
  • inert cores include sucrose, lactose, maltodextrin, microcrystalline cellulose, pregelatinized starch, dicalcium phosphate, celphere and non-pareils.
  • the cores may be of any geometric shape, though spheres are particularly used for the case of uniform coating.
  • the modified release unit which includes milnacipran or salt of milnacipran
  • the blend which includes milnacipran or salt of milnacipran and one or more rate-modifying agents (rate- controlling/enteric agents) may be layered onto inert cores as powder or as suspension or solution in a suitable solvent.
  • the modified release unit can also be prepared by providing a coating of rate- modifying agents (rate-controlling/enteric agents) over the immediate release units that include milnacipran or salt of milnacipran.
  • rate-modifying agents rate-controlling/enteric agents
  • the modified release unit can contain the combination of both rate-controlling and enteric agents.
  • the controlled release unit that includes milnacipran or salt of milnacipran can be formulated by blending milnacipran or salt of milnacipran with one or more rate- controlling agents and other pharmaceutically acceptable excipients, by the processes known in the art, such as, simple granulation followed by sieving; extrusion and marumerization or spheronization; rotogranulation; pelletization; micropelletization, etc.
  • the blend that includes milnacipran or salt of milnacipran and one or more rate-controlling agents may be layered onto inert cores as powder or as suspension or solution in a suitable solvent.
  • the controlled release unit can also be prepared by providing a coating of rate- controlling agents over the immediate release units comprising milnacipran or salt of milnacipran.
  • the controlled release unit can contain the combination of both rate-controlling and rate-modifying agents.
  • the enteric release unit that includes milnacipran or salt of milnacipran can be formulated by blending milnacipran or salt of milnacipran with one or more enteric agents and other pharmaceutically acceptable excipients, by the processes known in the art, such as, simple granulation followed by sieving; extrusion and marumerization or spheronization; rotogranulation; pelletization; micropelletization, etc.
  • the blend that includes milnacipran or salt of milnacipran and one or more enteric agents may be layered onto inert cores as powder or as suspension or solution in a suitable solvent.
  • the enteric release unit can also be prepared by providing a coating of enteric agents over the immediate release units that include milnacipran or salt of milnacipran.
  • the enteric release unit can contain the combination of both rate- controlling and rate-modifying agents.
  • the enteric coated controlled release unit can be prepared by providing a coating of enteric agents over the controlled release units.
  • the rate-controlling agents can be hydrophilic or hydrophobic or combinations of both.
  • hydrophilic rate-controlling agents include cellulose derivatives such as hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, carboxymethylcellulose,
  • polyvinylpyrrolidone polyvinyl acetate, copolymer of vinylpyrrolidone and vinyl acetate, polysaccharides, polyalkylene glycols, starch, gums and derivatives; and combinations comprising one or more of the foregoing materials.
  • hydrophobic rate-controlling agents include ethyl cellulose, cellulose acetate, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate, poly (alkyl) methacrylate, and copolymers of acrylic or methacrylic acid esters, waxes, shellac, zein, castor oil, hydrogenated vegetable oils and combinations comprising one or more of the foregoing materials.
  • enteric agents/enteric polymers would facilitate erosion and breakdown of the composition in the pH of the lower GI tract.
  • the enteric polymer should be nontoxic and is predominantly soluble in the intestinal fluid, but substantially insoluble in the gastric juices.
  • enteric polymers include polyvinyl acetate phthalate
  • PVAP hydroxypropylmethyl-cellulose acetate succinate
  • HPMCAS hydroxypropylmethyl-cellulose acetate succinate
  • CAP cellulose acetate phthalate
  • methacrylic acid copolymer methacrylic acid copolymer
  • methacrylic acid/methacrylate polymer (acid number 300 to 330 and also known as Eudragit® L or Eudragit® S, which are anionic copolymers based on methacrylate and available as a powder) also known as methacrylic acid copolymer, type A NF, methacrylic acid- methyl methacrylate copolymer, ethyl methacryl
  • enteric polymers examples include natural resins, such as shellac, Sandarac®, copal collophorium, and combinations comprising one or more of the foregoing polymers.
  • enteric polymers include synthetic resins bearing carboxyl groups. The methacrylic acid:acrylic acid ethyl ester 1:1 copolymer solid substance of the acrylic dispersion sold under the trade designation Eudragit® L- 100-55 may be suitable.
  • the rate-controlling layers and enteric coating layers may contain one or more pharmaceutically acceptable plasticizers in order to obtain desirable mechanical properties, improve flexibility and strength of the coating.
  • plasticizers include triacetin, citric acid esters, triethyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, phthalic acid esters, diethyl phthalate, dibutyl sebacate, cetyl alcohol, polyethylene glycols, propylene glycol, triethylene glycol, polysorbates, oleic acid, ethyleneglycol monoleate, glyceryl monostearate, castor oil and mixtures thereof.
  • the modified release unit may also include one or more pore-formers.
  • the pore-formers can be organic or inorganic, and include one or more hydrophilic polymers, such as starch, gums, alginates,
  • polysaccharides polyvinylprrolidone, polyethylene glycol, acrylic acid derivatives, and cellulose derivatives like hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, carboxymethylcellulose,
  • methylcellulose sodium carboxy methylcellulose and mixtures thereof; polycarbonates comprised of linear polyesters of carbonic acid in which carbonate groups reoccur in the polymer chain.
  • suitable pore formers include small molecules such as lactose or metal stearates, and combinations that include one or more of the foregoing materials.
  • the coating layers over the composition may be applied as solution/dispersion of coating ingredients using any conventional technique known in the prior art such as spray coating in a conventional coating pan or fluidized bed processor or dip coating.
  • Example of solvents used for preparing a solution/dispersion of the coating ingredients include water, methanol, ethanol, acidified ethanol, acetone, diacetone, polyols, polyethers, oils, esters, alkyl ketones, methylene chloride, isopropyl alcohol, butyl alcohol, methyl acetate, ethyl acetate, isopropyl acetate, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethylsulphoxide, ⁇ , ⁇ -dimethylformamide, tetrahydrofuran, and mixtures thereof.
  • composition of the invention may contain suitable amounts of
  • pharmaceutically acceptable excipients that would be necessary for preparing appropriate dosage forms.
  • pharmaceutically acceptable excipients that can be used in the composition of the present invention include one or more diluents, binders, disintegrants, lubricants/glidants, surfactants, buffers, wetting agents, coloring agents, flavoring agents, and combinations thereof.
  • fillers or diluents include corn starch, lactose, white sugar, sucrose, sugar compressible, sugar confectioners, glucose, sorbitol, calcium carbonate, calcium dihydrogen phosphate dihydrates, calcium phosphate-dibasic, calcium phosphate- tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose, fructose, kaolin, lactitol, mannitol, starch and starch pregelatinized.
  • the fillers comprise lactose,
  • microcrystalline cellulose microcrystalline cellulose, calcium hydrogen phosphate dehydrate, or a mixture thereof.
  • binders include povidones, starches, corn starch, pregelatinized starch, microcrystalline celluloses (MCC), silicified MCC (e.g., Prosolv® HD 90), microfine celluloses, lactose, calcium carbonate, calcium sulfate, sugar, mannitol, sorbitol, dextrates, dextrin, maltodextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, magnesium carbonate, magnesium oxide, stearic acid, gums, hydroxypropyl methylcelluloses or hypromelloses (e.g., Klucel® EF, Methocel® E5 premium) and other pharmaceutically acceptable substances with cohesive properties.
  • MCC microcrystalline celluloses
  • silicified MCC e.g., Prosolv® HD 90
  • disintegrants examples include cross-linked polyvinyl pyrrolidone, corn starch, potato starch, maize starch and modified starches, agar-agar, calcium carbonate, sodium carbonate, alginic acids, cross- carmellose sodium, sodium starch glycolate, microcrystalline cellulose, and mixtures thereof.
  • lubricants and glidants examples include colloidal silicon dioxide, such as Aerosil® 200, talc, stearic acid, magnesium stearate, calcium stearate, solid polyethylene glycols, sodium stearyl fumarate, silica gel and mixtures thereof and other substances with lubricating or gliding properties.
  • colloidal silicon dioxide such as Aerosil® 200, talc, stearic acid, magnesium stearate, calcium stearate, solid polyethylene glycols, sodium stearyl fumarate, silica gel and mixtures thereof and other substances with lubricating or gliding properties.
  • surfactant is used in its conventional sense in the present invention. Any surfactant is suitable, whether it is amphoteric, non-ionic, cationic or anionic.
  • surfactants include sodium lauryl sulfate, polysorbates such as polyoxyethylene sorbitan monooleate, monolaurate, monopalmitate, monstearate or another ester of polyoxyethylene sorbitan (e.g., the commercially available Tweens), sodium dioctylsulfosuccinate (DOSS), lecithin, stearylic alcohol, cetostearylic alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, poloxamers (e.g., Pluronics F68® and Fl 08®, which are block copolymers of ethylene oxide and propylene oxide); polyoxyethylene castor oil derivatives, or mixtures thereof.
  • polysorbates such as polyoxyethylene sorbitan monooleate, monolaurate, monopalmitate, monstearate or another ester of polyoxyethylene sorbitan (e.g., the commercially available Tweens), sodium dioctylsulfo
  • buffers examples include phosphate, acetate, citrate, succinate and histidine buffers.
  • wetting agents examples include ammonium lauryl sulfate and sodium lauryl sulfate.
  • the coloring agents and flavoring agents of the present invention may be selected from any FDA approved colors and flavors for oral use.
  • the modified release composition of the present invention having multiple-units that include immediate release units of milnacipran or salts of milnacipran and modified release units of milnacipran or salts of milnacipran are filled into capsules or sachets or compressed into tablets.
  • the ratio of immediate release unit to the modified release unit(s) may range from about 5:95 to about 95:5 by weight.
  • the modified release composition of the present invention having multiple-units that include controlled release units of milnacipran or salts of milnacipran and enteric release units of milnacipran or salts of milnacipran are filled into capsules or sachets or compressed into tablets.
  • the ratio of controlled release unit to the enteric release unit(s) may range from about 5:95 to about 95:5 by weight.
  • composition of the invention may be used in treating conditions such as depression, fibromyalgia syndrome, chronic fatigue syndrome, pain, attention deficit/hyperactivity disorder, and visceral pain syndromes (VPS) such as irritable bowel syndrome (IBS), noncardiac chest pain (NCCP), functional dyspepsia, interstitial cystitis, essential vulvodynia, urethral syndrome, orchialgia, and affective disorders, including depressive disorders (major depressive disorder, dysthymia, atypical depression) and anxiety disorders (generalized anxiety disorder, phobias, obsessive compulsive disorder, panic disorder, post-traumatic stress disorder), premenstrual dysphoric disorder, temperomandibular disorder, atypical face pain, migraine headache, and tension headache.
  • IBS irritable bowel syndrome
  • NCCP noncardiac chest pain
  • functional dyspepsia interstitial cystitis
  • essential vulvodynia essential vulvodynia
  • the modified release composition of milnacipran may be administered in combination with other therapeutic agents such analgesics, anti-inflammatory drugs, antipyretics, antidepressants, antiepileptics, antihistamines, antimigraine drugs, antimuscarinics, anxioltyics, sedatives, hypnotics, antipsychotics, bronchodilators, anti asthma drugs, cardiovascular drugs, corticosteroids, dopaminergics, electrolytes, gastro-intestinal drugs, muscle relaxants, nutritional agents, vitamins,
  • Example 1 Modified Release Tablets of Milnacipran Hydrochloride
  • step (1) The granules of step (1) were dried and sized.
  • step (1) The blend of step (1) was extruded, spheronized and dried.
  • Coating solution was prepared by dispersing hydroxypropylmethylcellulose acetate succinate in the solution of triethyl citrate and sodium lauryl sulphate in purified water.
  • step (3) The pH of the dispersion of step (3) was maintained at 5.6 to 5.9 and talc was added.
  • step (2) The spheres of step (2) were coated with the coating preparation of step (4).
  • step (1) The blend of step (1) was extruded, spheronized and dried.
  • Coating solution was prepared by dispersing Eudragit® in purified water and adding ammonia solution.
  • step (2) The spheres of step (2) were coated with the coating preparation of step (4). Tablet compression
  • step (1) was lubricated with aerosol and magnesium stearate. 3.
  • the lubricated blend of step (2) was compressed into a tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet une composition à libération modifiée comprenant du milnacipran ou ses sels pharmaceutiquement acceptables, et un procédé pour sa préparation.
PCT/IB2011/050825 2010-03-04 2011-02-25 Composition de milnacipran à libération modifiée Ceased WO2011107921A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN479/DEL/2010 2010-03-04
IN479DE2010 2010-03-04

Publications (2)

Publication Number Publication Date
WO2011107921A2 true WO2011107921A2 (fr) 2011-09-09
WO2011107921A3 WO2011107921A3 (fr) 2012-07-26

Family

ID=44169175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/050825 Ceased WO2011107921A2 (fr) 2010-03-04 2011-02-25 Composition de milnacipran à libération modifiée

Country Status (1)

Country Link
WO (1) WO2011107921A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102793683A (zh) * 2012-09-04 2012-11-28 海南康虹医药科技开发有限公司 一种含左旋米那普仑的缓释组合物及其制备方法
EP3199167A1 (fr) 2016-01-28 2017-08-02 G.L. Pharma GmbH Medicament destine a traiter des carences en fer et en acide folique
EP3199145A1 (fr) 2016-01-28 2017-08-02 G.L. Pharma GmbH Formule stabilisee d'une preparation de fer/d'acides foliques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008495A1 (fr) 1996-08-28 1998-03-05 Pierre Fabre Medicament Forme galenique a liberation prolongee de milnacipran
WO2004037190A2 (fr) 2002-10-25 2004-05-06 Collegium Pharmaceutical, Inc. Compositions de milnaciprane a liberation modifiee
WO2004039361A1 (fr) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Compositions a liberation intermittente de milnaciprane
WO2004067039A1 (fr) 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Compositions multiparticulaires de milnacipran destinees a etre administrees par voie orale

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117872A2 (fr) * 2004-06-04 2005-12-15 Dynogen Pharmaceuticals, Inc. Antagonistes de snri-nmda a double action utilises pour traiter des troubles genito-urinaires
US20100040680A1 (en) * 2008-08-15 2010-02-18 Felix Lai Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008495A1 (fr) 1996-08-28 1998-03-05 Pierre Fabre Medicament Forme galenique a liberation prolongee de milnacipran
WO2004037190A2 (fr) 2002-10-25 2004-05-06 Collegium Pharmaceutical, Inc. Compositions de milnaciprane a liberation modifiee
WO2004039361A1 (fr) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Compositions a liberation intermittente de milnaciprane
WO2004067039A1 (fr) 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Compositions multiparticulaires de milnacipran destinees a etre administrees par voie orale

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102793683A (zh) * 2012-09-04 2012-11-28 海南康虹医药科技开发有限公司 一种含左旋米那普仑的缓释组合物及其制备方法
CN102793683B (zh) * 2012-09-04 2013-04-17 海南康虹医药科技开发有限公司 一种含左旋米那普仑的缓释组合物及其制备方法
EP3199167A1 (fr) 2016-01-28 2017-08-02 G.L. Pharma GmbH Medicament destine a traiter des carences en fer et en acide folique
EP3199168A1 (fr) 2016-01-28 2017-08-02 G.L. Pharma GmbH Médicament destine à traiter des carences en fer et en acide folique
EP3199145A1 (fr) 2016-01-28 2017-08-02 G.L. Pharma GmbH Formule stabilisee d'une preparation de fer/d'acides foliques

Also Published As

Publication number Publication date
WO2011107921A3 (fr) 2012-07-26

Similar Documents

Publication Publication Date Title
AU2012230733B2 (en) Methods and compositions for treatment of attention deficit disorder
CN109789096B (zh) 具有经改善药代动力学的γ-羟基丁酸盐改进释放制剂
MX2010005680A (es) Composiciones de tapentadol.
SK285359B6 (sk) Potiahnuté jadrá s oneskoreným uvoľňovaním účinnej látky a farmaceutické dávkovacie formy, ktoré ich obsahujú
US11883374B2 (en) Lacosamide pharmaceutical composition and dosage form thereof
KR20110005876A (ko) 다중 미립자를 함유하고 이중 방출 프로파일을 갖는 고체 경구용 제형
KR102276896B1 (ko) 파킨슨병의 고정용량 조합 치료법
CN119730840A (zh) 用于治疗重度抑郁症的1-(萘-2-基)-3-氮杂双环[3.1.0]己烷
US9504657B2 (en) Fixed dose combination therapy of Parkinson's disease
HK40107582A (en) Methods and compositions for treatment of attention deficit disorder
HK40073671A (en) Methods and compositions for treatment of attention deficit disorder
US20250177332A1 (en) Pharmaceutical dosage form of lacosamide
WO2011107922A2 (fr) Composition de milnacipran à libération prolongée
US20080299189A1 (en) Controlled release dopamine agonist compositions
HK40073671B (en) Methods and compositions for treatment of attention deficit disorder
RU2771522C9 (ru) Терапия болезни паркинсона с применением комбинации с фиксированными дозами
WO2022191957A1 (fr) Compositions à libération prolongée comprenant de l'atomoxétine
US20060069165A1 (en) Treating morning hypertension by lowering morning blood pressure levels with propranolol
AU2014246617A1 (en) Multi-layered, multiple unit pharmaceutical compositions
HK1203847B (en) Fixed dose combination therapy of parkinson's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11712677

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 11712677

Country of ref document: EP

Kind code of ref document: A2